Certainty Is the Exception, Not the Rule
Patients often expect medical tests to deliver clear, definitive answers: you have this condition, or you don't. In practice, most diagnostic decisions in gastroenterology operate on a spectrum of probability rather than a binary outcome. A fecal calprotectin of 120 µg/g does not say "you have IBD" or "you don't" — it adjusts the clinical probability based on pre-test likelihood, test sensitivity, and test specificity. This is Bayesian reasoning applied to medicine.
Pre-Test Probability
Before any test is ordered, a clinician estimates — consciously or unconsciously — the likelihood that a condition is present based on the patient's symptoms, age, risk factors, and clinical presentation. A 22-year-old with bloating, no alarm features, and symptom onset during university exams has a very different pre-test probability of IBD than a 45-year-old with bloody diarrhoea, weight loss, and a family history of Crohn's disease. The same test result means different things in these two patients.
Sensitivity and Specificity in Context
A test with 95% sensitivity will miss 5% of true positives (false negatives). A test with 90% specificity will incorrectly flag 10% of healthy individuals (false positives). When the pre-test probability of disease is low (say 5%), even a good test produces more false positives than true positives — a phenomenon that surprises many patients and some clinicians. This is why screening strategies target high-risk populations and why confirmatory testing follows positive screening results.
The Grey Zone
Many test results fall into an indeterminate range — neither clearly normal nor clearly abnormal. Fecal calprotectin between 50 and 200 µg/g, mildly elevated CRP in the context of obesity, or equivocal coeliac serology all occupy this grey zone. Management options include repeating the test after an interval, adding complementary investigations, or — when the clinical picture is reassuring — watchful waiting with clear safety-netting advice.
Living With Uncertainty
For patients, diagnostic uncertainty can be deeply unsettling. The phrase "we don't know yet" feels like a failure. But acknowledging uncertainty is not a weakness of the diagnostic process — it is a feature that protects against both overtesting (with its costs, false positives, and iatrogenic anxiety) and premature diagnostic closure (where a label is assigned too soon and competing diagnoses are overlooked). Shared decision-making — where clinicians explain the probabilities and patients participate in deciding next steps — transforms uncertainty from a source of anxiety into a collaborative, transparent process.
Practical Framework
Clinicians navigating diagnostic uncertainty can use a structured approach: (1) Estimate pre-test probability based on history and examination. (2) Select tests that meaningfully shift post-test probability — avoid tests that tell you nothing new. (3) Interpret results in context, not in isolation. (4) Communicate openly with the patient about what the results mean and what remains unknown. (5) Set a clear follow-up plan with defined triggers for re-evaluation.